InvestSMART

Cleo Diagnostics Ltd (ASX: COV) - Announcements

Current share price for COV : $0.310 0.025 (8.77%)+

ASX company news and announcements for Cleo Diagnostics Ltd (COV) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Cleo Diagnostics Ltd (COV) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Cleo Diagnostics Ltd (COV), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Cleo Diagnostics Ltd (COV)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$43 Cleo Files Patents for its Ovarian Cancer Screening Test 30 Sep 2026 8:52AM $0.280 $0.310 risen by 10.71%
$43 CLEO Commences Ovarian Cancer Screening Test Development 24 Sep 2026 9:09AM $0.305 $0.310 risen by 1.64%
$43 Letter to Shareholders 17 Sep 2026 10:18AM $0.315 $0.310 fallen by 1.59%
$43 Notice of Annual General Meeting/Proxy Form 17 Sep 2026 10:14AM $0.315 $0.310 fallen by 1.59%
$43 Notice Required Under ASX Listing Rule 3.13.1 10 Sep 2026 5:01PM $0.340 $0.310 fallen by 8.82%
$43 CLIA Certified Lab selected - Pivotal US Clinical Validation 10 Sep 2026 9:14AM $0.340 $0.310 fallen by 8.82%
$43 CLEO Receives First Batch of Commercial Test Kits 3 Sep 2026 8:55AM $0.350 $0.310 fallen by 11.43%
$43 Change of Director's Interest Notice x 4 24 Aug 2026 4:33PM $0.340 $0.310 fallen by 8.82%
$43 Cleansing Notice 24 Aug 2026 4:16PM $0.340 $0.310 fallen by 8.82%
$43 Application for quotation of securities - COV 24 Aug 2026 4:14PM $0.340 $0.310 fallen by 8.82%
$43 Notification of cessation of securities - COV 24 Aug 2026 4:12PM $0.340 $0.310 fallen by 8.82%
$43 Change in Director's Interest Notice 21 Aug 2026 4:22PM $0.318 $0.310 fallen by 2.36%
$43 Appendix 4G and Corporate Governance Statement 20 Aug 2026 4:01PM $0.330 $0.310 fallen by 6.06%
$43 Appendix 4E and 2026 Annual Report 20 Aug 2026 3:52PM $0.330 $0.310 fallen by 6.06%
$43 Quarterly activities and cashflow report 29 Jul 2026 9:39AM $0.320 $0.310 fallen by 3.13%
$43 CLEO Enters Analytical Validation Phase 13 Jul 2026 9:10AM $0.510 $0.310 fallen by 39.22%
$43 Change in Director's Interest Notice 7 Jul 2026 4:41PM $0.495 $0.310 fallen by 37.37%
$43 Cleansing Notice 28 May 2026 4:18PM $0.585 $0.310 fallen by 47.01%
$43 Application for quotation of securities - COV 28 May 2026 4:12PM $0.585 $0.310 fallen by 47.01%
$43 CLEO Establishes U.S. Reimbursement Pathway 20 May 2026 9:25AM $0.635 $0.310 fallen by 51.18%
$43 Quarterly activities and cashflow report 29 Apr 2026 9:32AM $0.625 $0.310 fallen by 50.40%
$43 CLEO Commences Kit Manufacturing Ahead of FDA Submission 28 Apr 2026 8:26AM $0.625 $0.310 fallen by 50.40%
$43 Sample Collection Completion for Pivotal US Clinical Trial 31 Mar 2026 9:04AM $0.535 $0.310 fallen by 42.06%
$43 CLEO Optimises Biomarker Panel Ahead of FDA Submission 23 Mar 2026 8:29AM $0.480 $0.310 fallen by 35.42%
$43 Appendix 4D and Half Yearly Accounts 25 Feb 2026 4:24PM $0.600 $0.310 fallen by 48.33%

1 - 25 of 152 results

Page 1 of 7

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.